Mizuho Initiates Coverage On Adverum Biotechnologies with Buy Rating, Announces Price Target of $2
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Graig Suvannavejh has initiated coverage on Adverum Biotechnologies (NASDAQ:ADVM) with a Buy rating and a price target of $2.
November 02, 2023 | 9:52 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Adverum Biotechnologies has been initiated with a Buy rating by Mizuho, with a price target of $2.
The initiation of coverage by Mizuho with a Buy rating is a positive signal for Adverum Biotechnologies. This could potentially attract more investors to the stock, driving up its price in the short term. The price target of $2 also provides a clear expectation of the stock's potential value.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100